IGHE and allergic asthma: Omalizumab (Xolair; Novartis, Switzerland), which isa humanized anti-IgE monoclonal antibody (mAb)that selectively binds to human IgE and prevents thebinding of IgE to its receptors, is an add-on treatmentoption effective in the treatment of patients withsevere allergic asthma (4).